Tumor News and Research

RSS

Protein imbalances within cells can cause ovarian cancer

Cancer can be caused solely by protein imbalances within cells, a study of ovarian cancer has found. The discovery is a major breakthrough because, until now, genetic aberrations have been seen as the main cause of almost all cancer.

28 Jul 2015

Study: Omega-3 fatty acids may help improve treatment response, quality of life for patients with cancer

Adding omega-3 fatty acids to anti-tumor medications may improve treatment response and quality of life for cancer patients according to a new study by researchers at the University Hospitals of Leicester in the United Kingdom.

28 Jul 2015

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and Hannover has now succeeded in decoding a specific form of this leukemia, which is regarded as incurable, and in obtaining insights for new therapeutic possibilities.

28 Jul 2015

Simple and accurate detection system can redefine medical diagnostics field

In biology and medicine, we often need to detect biological molecules. For example, in cancer diagnostics, doctors need quick and reliable ways of knowing if tumor cells are present in the patient's body.

25 Jul 2015

Study points to new treatment strategies for liver cancer

A new study by researchers at Sanford Burnham Prebys Medical Discovery Institute, the National Cancer Institute, and the Chulabhorn Research Institute has found that blocking the activity of a key immune receptor, the lymphotoxin-beta receptor (LTβR), reduces the progression of liver cancer.

25 Jul 2015

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Novartis today announced the US Food and Drug Administration has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.

25 Jul 2015

Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

An algorithm dubbed ENVE could be the Google for genetic aberrations — and it comes from Case Western Reserve.

24 Jul 2015

3SBio purchases entire equity interest in Zhejiang Wansheng

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that it has acquired the entire equity interest in Zhejiang Wansheng Pharmaceutical Co., Ltd a limited liability company incorporated in the PRC for an aggregate consideration of RMB 528 million.

24 Jul 2015

Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.

24 Jul 2015

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.

24 Jul 2015

New interactive tool helps researchers explore genetic underpinnings of cancer

Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.

23 Jul 2015

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy.

23 Jul 2015

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

PharmaMar has entered into an exclusive license and commercialization agreement with the pharmaceutical company TTY Biopharm to market and distribute the drug candidate APLIDIN (plitidepsin) in Taiwan. Under the terms of the agreement, PharmaMar will receive an upfront payment, royalties and additional remunerations for regulatory milestones achieved by APLIDIN (plitidepsin).

23 Jul 2015

Experts to highlight new diagnostic products, tools to identify heart attacks at 2015 AACC Annual Meeting

The 2015 AACC Annual Meeting & Clinical Lab Expo, the leading annual event for laboratory medicine, will open on Sunday, July 26, in Atlanta, Georgia. This year's meeting will host more than 400 educational sessions on topics ranging from personalized medicine and infectious diseases to point-of-care and laboratory-developed tests, and will feature more than 200 new cutting edge diagnostic products.

23 Jul 2015

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

AstraZeneca today announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib.

23 Jul 2015

Gene responsible for cancer growth plays unexpected role in prostate cancer

A gene that is responsible for cancer growth plays a totally unexpected role in prostate cancer. The gene Stat3 is controlled by the immune modulator interleukin 6 and normally supports the growth of cancer cells. The international research team led by Prof. Lukas Kenner from the Medical University of Vienna, the Veterinary University of Vienna, and the Ludwig Boltzmann Institiute for Cancer Research (LBI-CR) discovered a missing link for an essential role of Stat3 and IL-6 signalling in prostate cancer progression.

22 Jul 2015

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).

22 Jul 2015

New phase III cancer treatment trial opens for patient with advanced melanoma

A new phase III cancer treatment trial has opened for patient enrollment that examines two treatments that work in completely different ways yet have both been shown in previous clinical trials to be effective in treating patients with advanced melanoma, the ECOG-ACRIN Cancer Research Group announced today.

22 Jul 2015

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that data from its Phase I/II study of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published in Nature Medicine.

22 Jul 2015

Tumor News and Research

Protein imbalances within cells can cause ovarian cancer

Study: Omega-3 fatty acids may help improve treatment response, quality of life for patients with cancer

Research sheds light on new therapeutic options for acute lymphoblastic leukemia

Simple and accurate detection system can redefine medical diagnostics field

Study points to new treatment strategies for liver cancer

Novartis announces FDA approval of Odomzo (sonidegib) 200 mg capsules for treatment of laBCC patients

Case Western cancer researchers develop algorithm to detect DNA copy-number alterations in tumors

3SBio purchases entire equity interest in Zhejiang Wansheng

Moffitt researchers develop genetic test that analyzes sensitivity of tumors to radiation therapy

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

Mayo Clinic researchers study HDAC inhibitors to find effective treatments for anaplastic thyroid cancer

New interactive tool helps researchers explore genetic underpinnings of cancer

Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis (carfilzomib)

PharmaMar, TTY Biopharm sign agreement to market and distribute APLIDIN (plitidepsin) in Taiwan

Experts to highlight new diagnostic products, tools to identify heart attacks at 2015 AACC Annual Meeting

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Gene responsible for cancer growth plays unexpected role in prostate cancer

New TCR therapy demonstrates encouraging clinical responses in patients with multiple myeloma

New phase III cancer treatment trial opens for patient with advanced melanoma

Adaptimmune’s NY-ESO-1 TCR-engineered T-cell therapy mediates sustained antitumor effects in multiple myeloma patients

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News